Effects of Efpeglenatide on Body Weight, BMI, and Waist Circumference in Patients With Obesity Without Diabetes Stratified by Baseline Characteristics: A Subanalysis of BALANCE 205

Publication Authors:

Pratley, R.E.; Jacob, S; Kang, J; Trautmann, M.E.; Hompesch, M; Han, O; Stewart, J.A.; Ogbaa, I; Sorli, C.H.; Yoon, K

Poster presented at European Association for the Study of Diabetes (EASD), Barcelona, September 2019

About this Poster:

Once-weekly (QW) subcutaneous efpeglenatide is a long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA) being developed to improve glycaemic control in patients with type 2 diabetes mellitus. In the BALANCE 205 study in patients with obesity (median BMI 34.9 [28.1−57.7] kg/m2) without diabetes, all doses of efpeglenatide (4 or 6 mg QW; 6 or 8 mg once every 2 weeks [Q2W]) significantly reduced body weight (BW) from baseline (BL) to week 21 vs placebo (PBO, p<0.0001; primary endpoint). In this exploratory subgroup analysis, the effects of efpeglenatide (in each treatment arm or pooled data) on BW, BMI, and waist circumference (WC) from BL to week 21 vs PBO were investigated in patients stratified by BMI, WC, and age (< or ≥ median BL values).